These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 27200300)

  • 21. Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer.
    Sood S; Ju AW; Wang H; Lei S; Uhm S; Zhang G; Suy S; Carroll J; Lynch J; Dritschilo A; Collins SP
    Radiat Oncol; 2013 Aug; 8():197. PubMed ID: 23937800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bothersome Hot Flashes Following Neoadjuvant Androgen Deprivation Therapy and Stereotactic Body Radiotherapy for Localized Prostate Cancer.
    Shah S; Pepin A; Jatar S; Hsueh J; Gallagher L; Danner MT; Zwart A; Ayoob M; Yung TM; Kumar D; Aghdam N; Leger PD; Dawson NA; Simeng S; Collins SP
    Cureus; 2024 Mar; 16(3):e55729. PubMed ID: 38586683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
    Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M
    Technol Cancer Res Treat; 2010 Dec; 9(6):575-82. PubMed ID: 21070079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.
    Chen LN; Suy S; Wang H; Bhagat A; Woo JA; Moures RA; Kim JS; Yung TM; Lei S; Collins BT; Kowalczyk K; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2014 Jun; 9():148. PubMed ID: 24966110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer.
    Woo JA; Chen LN; Bhagat A; Oermann EK; Kim JS; Moures R; Yung T; Lei S; Collins BT; Kumar D; Suy S; Dritschilo A; Lynch JH; Collins SP
    Front Oncol; 2014; 4():122. PubMed ID: 24904833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer.
    Meier R
    Front Oncol; 2015; 5():48. PubMed ID: 25905037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is Ultrahypofractionated Whole Pelvis Radiation Therapy (WPRT) as Well Tolerated as Conventionally Fractionated WPRT in Patients With Prostate Cancer? Early Results From the HOPE Trial.
    Mendez LC; Crook J; Martell K; Schaly B; Hoover DA; Dhar A; Velker V; Ahmad B; Lock M; Halperin R; Warner A; Bauman GS; D'Souza DP
    Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):803-812. PubMed ID: 38072323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with Localized Prostate Cancer.
    Moon DH; Basak RS; Usinger DS; Dickerson GA; Morris DE; Perman M; Lim M; Wibbelsman T; Chang J; Crawford Z; Broughman JR; Godley PA; Chen RC
    Eur Urol; 2019 Sep; 76(3):391-397. PubMed ID: 30857758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer.
    Phak JH; Kim HJ; Kim WC
    Prostate Int; 2016 Mar; 4(1):25-9. PubMed ID: 27014661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancer.
    Rana Z; Cyr RA; Chen LN; Kim BS; Moures RA; Yung TM; Lei S; Collins BT; Suy S; Dritschilo A; Lynch JH; Collins SP
    Front Oncol; 2014; 4():290. PubMed ID: 25374844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer.
    Kishan AU; Wang PC; Upadhyaya SK; Hauswald H; Demanes DJ; Nickols NG; Kamrava M; Sadeghi A; Kupelian PA; Steinberg ML; Prionas ND; Buyyounouski MK; King CR
    Pract Radiat Oncol; 2016; 6(4):268-275. PubMed ID: 26850649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study.
    Katz AJ; Kang J
    Front Oncol; 2014; 4():301. PubMed ID: 25389521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer.
    Arscott WT; Chen LN; Wilson N; Bhagat A; Kim JS; Moures RA; Yung TM; Lei S; Collins BT; Kowalczyk K; Suy S; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2014 Jul; 9():163. PubMed ID: 25056726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utilization of Patient-Reported Outcomes to Guide Symptom Management during Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer.
    Danner M; Hung MY; Yung TM; Ayoob M; Lei S; Collins BT; Suy S; Collins SP
    Front Oncol; 2017; 7():227. PubMed ID: 29085804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
    Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
    Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
    Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Multicenter Phase 2 study of Hypofractionated Stereostatic Boost in Intermediate Risk Prostate Carcinoma: A 5-Year Analysis of the CKNO-PRO Trial.
    Pasquier D; Peiffert D; Nickers P; Maingon P; Pommier P; Lacornerie T; Martinage G; Tresch E; Lartigau E
    Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):116-123. PubMed ID: 31604131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Irradiation of localized prostate cancer in the elderly: A systematic literature review.
    Marotte D; Chand-Fouche ME; Boulahssass R; Hannoun-Levi JM
    Clin Transl Radiat Oncol; 2022 Jul; 35():1-8. PubMed ID: 35492872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients.
    Marina O; Gustafson GS; Kestin LL; Brabbins DS; Chen PY; Ye H; Martinez AA; Ghilezan MI; Wallace M; Krauss DJ
    Brachytherapy; 2014; 13(1):59-67. PubMed ID: 23871661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of prostate boost with high-dose-rate brachytherapy versus intensity-modulated radiation therapy in the treatment of intermediate-high risk prostate cancer.
    Vu CC; Blas KG; Lanni TB; Gustafson GS; Krauss DJ
    Brachytherapy; 2018; 17(6):852-857. PubMed ID: 30076108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.